Pfizer Inc. (PFE)
Pfizer Makes an Unusual Enemy in $2 Billion Fight Over Unwanted Covid-19 Vaccines
The drugmaker has targeted air-traffic control fees in a dispute with Poland and Romania.
Pfizer: Firing On All Cylinders
Pfizer (PFE) remains a strong buy as guidance is reaffirmed and raised, with acquired assets compounding at 18% operationally. PFE's pipeline strength is evident, especially in obesity (berobenatide) and Vyndamax, providing a bridge over the 2028 LOE trough. Valuation is highly attractive: P/E of 9.11, EV/EBITDA of 8.29, and a 6.19% dividend yield, with disciplined capital allocation.
Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?
PFE's non-COVID growth, oncology pipeline and cost cuts offer a path forward as COVID sales fall and patent losses loom.
Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now
Pfizer's 5.91% dividend yield anchors the story, and a pipeline finally catching a bid adds meaningful upside. My 24/7 Wall St. price target reflects that.
Pfizer's Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?
Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company's toughest stretch in years.
Pfizer (PFE) Up 12.4% Since Last Earnings Report: Can It Continue?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?
Pfizer's Pipeline Strategy Centers on Obesity and Oncology
PFE's pipeline is taking center stage as berobenatide and next-generation oncology drugs aim to drive growth from 2028 and beyond.
From Padcev to PF-08634404: Pfizer's Oncology Growth Push
PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.
Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn't
Pfizer and Starbucks both raised their outlooks this summer, but a louder recovery and a quieter one are not the same thing, and for investors who need a portfolio to fund actual withdrawals, the difference matters enormously.
PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?
PFE and BMY both boast strong oncology portfolios, but Pfizer's valuation and broader diversification make it the more attractive pick now.
Pfizer Stock: Wall Street Sees a Rebound, Here's Our Price Target
Our 24/7 Wall St. price target for Pfizer (NYSE:PFE | PFE Price Prediction) points to $32.36 over the next 12 months, implying 15.27% upside from the recent close of $28.07.
Pfizer: Patient Investors Will Be Rewarded
Pfizer remains significantly undervalued, demonstrating robust profitability and offering an attractive forward dividend yield above 6%. PFE's diversified product roadmap and disciplined capital allocation help offset LOE uncertainties and COVID revenue declines, stabilizing business variability. Oncology pipeline progress, bolstered by the Seagen acquisition, provides credible growth pathways beyond early clinical stages, anchoring the long-term growth optionality.
